Thomas Michel is co-faculty lead of the Leder Human Biology and Translational Medicine Program for Harvard Catalyst. Michel is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH), and professor of medicine (biochemistry) at Harvard Medical School. Additionally, he is a member of the Leadership Council of the Harvard/Massachusetts Institute of Technology MD-PhD Program. Michel’s clinical interests include general cardiology and ischemic heart disease. His research lab uses biochemical and cell biological approaches to understand signal transduction pathways in the cardiovascular system. He has studied endothelial nitric oxide synthase (eNOS), a signaling enzyme involved in the control of vascular tone, myocardial contractibility and platelet aggregation. His lab has developed chemogenetic approaches to modulate oxidative stress in vivo using novel transgenic mouse lines, leading to the development of new animal models for heart failure and arterial dysfunction. After graduating from Harvard College, Michel received his MD and PhD degrees from Duke University School of Medicine. He completed an internal medicine residency and clinical cardiology fellowship at BWH, and pursued postdoctoral fellowship training at HMS.